27
Mon, Mar
28 New Articles
  • Chemotherapy as a Tablet Instead of an Intravenous Infusion: A Benefit for the Patient

    Mar 27, 2017 | 14:45 pm

    Defence ceremony and presentation of doctoral degree, Emilia Sawicki, Utrecht University, the Netherlands 29 March 2017, 2:30 PMUtrecht, The Netherlands, March 27,2017 B3C newswire – Coming Wednesday (29 March 2017), Dutch pharmacist Emilia Sawicki will be defending her doctoral thesis in which she describes how some anticancer medicines can be formulated in such a way that patients take chemotherapy orally[…]

    Read more...
  • ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

    Mar 27, 2017 | 11:00 am

    LEIDEN, the Netherlands, March27, 2017(GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in translational medicine, rare disease drug development, and RNA therapeutics. Dr. Rodman’s experience includes a leadership role in developing two approved medicines[…]

    Read more...
  • Kraig Biocraft Laboratories Awarded Investment Certificate in Vietnam

    Mar 27, 2017 | 10:05 am

    ANN ARBOR, Mich., March27, 2017(GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that it has just been awarded an Investment Certificate for the production of high technology silk in Vietnam’s Quang Nam province.Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7c230223-69db-4576-a3e4-8500fefc755ahttp://www.globenewswire.com/NewsRoom/AttachmentNg/f4270bea-47a5-4294-ade1-d4a7ed9fe068http://www.globenewswire.com/NewsRoom/AttachmentNg/71d215d0-a16b-4e07-ab4d-c3bb98aff146The Investment Certificate was issued to the Company during the March[…]

    Read more...
  • Arbutus Announces Appointment of Daniel Burgess to Board of Directors

    Mar 23, 2017 | 20:30 pm

    VANCOUVER, B.C. and DOYLESTOWN, Pa., March23, 2017(GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company has appointed Daniel Burgess to the Board of Directors and Audit Committee effective immediately.Mr. Burgess has more than 25 years of executive level operating experience in biotech companies, including substantial experience in the[…]

    Read more...
  • Neothetics Provides Business Update and Reports Fourth Quarter 2016Financial Results

    Mar 23, 2017 | 12:00 pm

    SAN DIEGO, March23, 2017(GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016.“We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’[…]

    Read more...
  • Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference

    Mar 23, 2017 | 11:00 am

    NEW YORK, March23, 2017(GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference on April 5, 2017 at 8:40 AM Eastern Time. The conference will[…]

    Read more...
  • Vital Therapies Announces Pricing of Public Offering of Common Stock

    Mar 22, 2017 | 13:06 pm

    SAN DIEGO, March22, 2017(GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the pricing of an underwritten public offering of 8,750,000 newly issued shares of its common stock at a price to the public of $4.00 per share for gross proceeds of approximately $35.0[…]

    Read more...
  • BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017

    Mar 22, 2017 | 12:30 pm

    NEW YORK, March22, 2017(GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s Chief Medical Officer and Head of Business Development, Ramon Mohanlal, M.D., Ph.D., M.B.A., will present clinically and statistically significant data on BeyondSpring’s lead asset, Plinabulin, for the prevention of chemotherapy-induced Neutropenia at[…]

    Read more...
  • Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference

    Mar 22, 2017 | 11:30 am

    SOUTH SAN FRANCISCO, Calif., March22, 2017(GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that preclinical data for CK-2127107 were presented at the MDA Scientific Conference in Arlington, VA, showing that this next-generation fast skeletal troponin activator (FSTA) improves muscle function in mouse models of spinal muscular atrophy (SMA). In collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas"), Cytokinetics is developing CK-2127107[…]

    Read more...
  • Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

    Mar 21, 2017 | 20:54 pm

    PHILADELPHIA and OXFORD, United Kingdom, March21, 2017(GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may[…]

    Read more...
  • USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors

    Mar 21, 2017 | 20:05 pm

    NEW HAVEN, Conn., March21, 2017(GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No. 9,598,446 has been granted with claims to compositions of matter for compounds that inhibit complement factor D activity, a key[…]

    Read more...
  • Vital Therapies Announces Proposed Public Offering of Common Stock

    Mar 21, 2017 | 20:01 pm

    SAN DIEGO, March21, 2017(GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. In addition, Vital Therapies expects to grant the underwriters of the offering a 30-day option[…]

    Read more...
  • RedHill Biopharma Announces First Patient Dosed in theOpen-Label Extension Study to the Phase III Study with RHB-104for Crohn’s Disease

    Mar 21, 2017 | 14:45 pm

    A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension study (the MAP US2 study) is intended to assess the safety and efficacy of RHB-104 in patients who have completed 26 weeks of treatment in the ongoing MAP US[…]

    Read more...
  • Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock

    Mar 21, 2017 | 13:19 pm

    NEW YORK, March21, 2017(GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering of 3,743,316 shares of its common stock at a public offering price of $3.74 per share. The gross proceeds from the offering, before deducting the[…]

    Read more...
  • CURE Pharmaceutical Announces Product Development and Licensing Deal with Diverse International Pharmaceutical Company Meroven, Ltd.

    Mar 21, 2017 | 12:30 pm

    OXNARD, Calif., March21, 2017(GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs), today announces a product development and license agreement with Dublin, Ireland-based Meroven, Ltd. (“Meroven”), for the development of oral thin film delivery for several molecules.“We[…]

    Read more...
  • Arbutus Announces Year-End 2016 Financial Results

    Mar 21, 2017 | 11:30 am

    3 HBV Product Candidates in the Clinic in 1Q17Cash Runway into Late 2018Company to Host a Corporate Update Conference Call Today at 2:00 PM ETVANCOUVER, British Columbia and DOYLESTOWN, Pa., March21, 2017(GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its 2016 financial results and provided a corporate update.“Arbutus made significant[…]

    Read more...
  • Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

    Mar 21, 2017 | 11:00 am

    BERKELEY HEIGHTS, N.J., March21, 2017(GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2016 financial results on Tuesday, March 28, 2017. The Company will host a[…]

    Read more...
  • European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint® Test with Highest Level 1A Clinical Evidence

    Mar 21, 2017 | 09:15 am

    German (http://www.b3cnewswire.com/images/client_pictures/Instictif/PR60/22032017_pressemitteilung_agendia_egtm.pdf).MammaPrint® is the first and only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT trial

    Read more...
  • Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

    Mar 17, 2017 | 11:50 am

    Selvita (https://selvita.com/) (WSE:SLV),a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced today that the first patient was dosed with SEL24 (https://selvita.com/research-and-development/sel24/) in a Phase I/II clinical trial, for acute myeloid leukemia (AML).SEL24 is a Selvita-developed first-in-class dual PIM/FLT3 kinase inhibitor with a unique activity profile in oral formulation. It is intended[…]

    Read more...
  • Genomic Health Unveils a Wealth of Data for the Oncotype DX® Breast Cancer Test, Reinforcing Its Value in Improving Patient Outcomes and Leading to More Cost-Effective Management

    Mar 17, 2017 | 09:45 am

    Genomic Health (http://www.genomichealth.com/) today announced the

    Read more...
  • Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

    Mar 13, 2017 | 23:45 pm

    Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitorNovartis drug Kisqali® (ribociclib, LEE011) receives marketing approval by the US FDA as a first-line drug for HR+/HER2- advanced breast cancer in combination with an aromatase inhibitorAstex’s scientific expertise was instrumental in the drug’s discovery by[…]

    Read more...
  • Selvita to Present New Data from its Oncology Programs at the Upcoming AACR Annual Meeting 2017

    Mar 13, 2017 | 14:00 pm

    Selvita (https://selvita.com/) (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the upcoming AACR Annual Meeting 2017, which will place on April 1-5 2017, in Washington, DC, USA.Data presented at the conference will include recent results from Selvita’s most advanced oncology program,[…]

    Read more...
  • German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence

    Mar 8, 2017 | 10:00 am

    Agendia, Inc. (http://www.agendia.com), a world leader in personalized medicine and molecular cancer diagnostics, announces that the company’s MammaPrint® (http://www.agendia.com/healthcare-professionals/breast-cancer/mammaprint/) 70-Gene Breast Cancer Risk-of-Recurrence test is now included with the highest medical evidence level 1A in the latest version of

    Read more...
  • Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

    Mar 6, 2017 | 09:00 am

    Hookipa Biotech AG (http://hookipabiotech.com/), a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and Development. The appointment is effective from today.Dr. Matushansky joins Hookipa from Daiichi Sankyo, where he was the Global Head of Translational Development for Oncology. He led Daiichi Sankyo’s international[…]

    Read more...
  • Apollo Therapeutics: Funding of Four Initial Projects and Operational Update

    Feb 22, 2017 | 10:00 am

    Apollo Therapeutics (http://apollotherapeutics.com/) (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, has invested in and launched the first

    Read more...
  • AmpTec and CMC Pharma Close Consulting Agreement about API-mRNA Production for IND/CTA Use in Early Phase Clinical Studies

    Feb 21, 2017 | 10:00 am

    AmpTec GmbH (http://www.amp-tec.com) is an ISO 13485:2009 certified Provider of High Quality synthetic nucleic acids for worldwide leading companies in the fields of molecular diagnostics, biotechnology and therapeutic applications. AmpTec GmbH benefits from nearly 20 years experience in the production of Very Long Synthetic RNAs and has proudly teamed up with the leading manufacturers

    Read more...
  • CellGenix Headquarters Expands to Meet the Increasing Demands for GMP Cell Culture Reagents

    Feb 21, 2017 | 09:00 am

    CellGenix (http://www.cellgenix.com/), a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, started facility expansions as more customers approach late-stage clinical development and commercialization.Through early 2018, research and development laboratory as well as production and warehouse space will be added to its German headquarters in Freiburg. Consequently, new positions in research and development as[…]

    Read more...
  • Sartorius Enters Into a Corporate Partnership Program with the European Molecular Biology Laboratory (EMBL)

    Feb 17, 2017 | 11:30 am

    Sartorius (http://www.sartorius.com), a leading international laboratory and pharmaceutical equipment supplier, yesterday announced a partnership with EMBL, the European Molecular Biology Laboratory. EMBL is one of the Europe’s leading research institutions with global reach. It includes many research sites, such as Heidelberg and Hamburg in Germany, Hinxton in the

    Read more...
  • Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

    Feb 16, 2017 | 10:00 am

    Polyganics (http://www.polyganics.com/), a privately held medical technology company, announced today that interim results show a sharp improvement in pain reduction observed across patients currently enrolled within the “STOP NEUROMA” study.Enrolment was recently completed for the European “STOP NEUROMA” (Surgical Treatment Of symPtomatic Neuroma) which was designed to gather evidence

    Read more...
  • MammaTyper® Enables More Precise Prediction of the Response to Neoadjuvant Chemotherapy Compared to Manual or Digitalized IHC

    Feb 15, 2017 | 14:00 pm

    First comparison of a biomarker analysis by RT-qPCR (MammaTyper®) versus visual or computer-assisted immunohistochemistry (IHC) in subtyping mammary carcinomasSignificantly more precise prediction of pathologically complete remission in a neoadjuvant setting with MammaTyper® compared to manual or computer-assisted IHC; better therapy stratification and possible avoidance of unnecessary therapiesMammaTyper® provides reliable quantitative determination of MKI67-mRNA expressionMainz, Germany, February 15, 2017 B3C newswire[…]

    Read more...